|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
11 April 2016 |
|
Main ID: |
NCT02212249 |
|
Date of registration:
|
23/04/2014 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis
Sclerocadh1 |
|
Scientific title:
|
Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis |
|
Date of first enrolment:
|
May 2014 |
|
Target sample size:
|
85 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02212249 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
France
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- group 1: systemic sclerosis
- group 2: raynaud primary disease
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Primary Raynaud Disease
|
|
Systemic Sclerosis
|
|
Intervention(s)
|
|
Biological: soluble Ve cadherin
|
|
Primary Outcome(s)
|
|
Level of soluble Ve-cadherin and antibody VE-cadherin with ELISA TEST in Scleroderma group versus Primary Raynaud's Phenomenon
[Time Frame: At 30 days average]
|
|
Secondary ID(s)
|
|
2014-A00186-41
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|